Non-DSG3 mRNAs with partial complementarity

Non-DSG3 mRNAs with partial complementarity refers to a group of messenger RNA (mRNA) molecules that are not the intended target (Desmoglein-3) but share sequence similarity that allows for unintended binding by RNA-based therapeutics (Jackson et al., 2003). This is a critical safety consideration for drugs like small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) designed to treat conditions such as Pemphigus Vulgaris or head and neck squamous cell carcinoma by silencing DSG3 (Chen et al., 2007). This group often includes other members of the desmoglein family, such as DSG1, DSG2, and DSG4, which share high sequence homology with DSG3. When these drugs bind to non-target mRNAs through partial complementarity—often involving the seed region of the siRNA—they can trigger mRNA degradation or inhibit translation, mimicking the action of endogenous microRNAs (Birmingham et al., 2006). This unintended silencing can lead to off-target toxicity, potentially causing adverse effects or confounding experimental results. Consequently, these molecules are not therapeutic targets themselves but rather represent a significant challenge in achieving high drug specificity and safety. Identifying and minimizing interactions with these transcripts is a key step in the preclinical development and toxicological assessment of sequence-specific RNA medicines.

Other names

Off-target mRNAsPartial match transcriptsSeed-match off-targetsNon-specific mRNA targets

Unintended gene silencing via partial sequence complementarity, typically mediated by the RNA-induced silencing complex (RISC) through a microRNA-like mechanism.